The US Food and Drug Administration sees little benefit from the oral administration of GSK plc’s daprodustat for treatment of anemia in chronic kidney disease (CKD) patients, an assessment that may impact the approvability of the drug in the non-dialysis population and its uptake in the dialysis population.
FDA Says Safety Concerns May Negate Any Oral Dosing Advantage For GSK’s Anemia Treatment
When a drug’s biggest advantage becomes its potential downfall: The agency worries that chronic kidney disease patients not receiving dialysis may have worse outcomes on GSK’s anemia treatment daprodustat compared to ESA because of less patient safety monitoring as a result of the drug’s oral administration.
More from US FDA Performance Tracker
More from Regulatory Trackers
• By
The European Medicines Agency is set to issue opinions this week on whether pan-EU marketing approval should be granted to a number of new products.
• By
The US FDA approval of new meningococcal and chikungunya vaccines arrived in time for the 26-28 February meeting of the CDC’s Advisory Committee On Immunization Practices, if political developments allow.
• By
Two investigational products have made it onto the European Medicines Agency’s priority medicines scheme so far this year. Meanwhile, of the 14 products that entered the scheme last year, six were advanced therapies.